Heat Biologics' Announces Planned Investor And Media Livestream Event To Discuss Latest Developments For April 19

4/14/22 12:37:38 PM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $HTBX alert in real time by email

Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, today announced it plans to host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31

Get the next $HTBX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$HTBX

Date	Price Target	Rating	Analyst

More analyst ratings

$HTBX
Leadership Updates

Live Leadership Updates

Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company
DURHAM, N.C., March 23, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, announces the appointment of Greg Burel, former Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR) Director of the Strategic National Stockpile (SNS), to the Company's Biothreat Advisory Board and as a senior advisor to the Company. Mr. Burel served as the Director of SNS from March 2007 to January 2020. In this role, Mr. Burel directed the nation's premier medical materiel prepared
3/23/22 8:30:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy
DURHAM, N.C., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced the appointment of Paul Tebbey, Ph.D. as Senior Vice President of Product Development and Portfolio Strategy. Dr. Tebbey is a pharmaceutical development strategy leader with over 25 years of healthcare and management experience across the biotechnology and pharmaceutical sectors at companies such as Abbvie, Baxter, Centocor/Johnson & Johnson and Wyeth/Pfizer. Dr. Tebbey's research, development and commercial launch experiences include novel monoclonal antibodies
10/6/21 7:30:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor
DURHAM, N.C., May 10, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NASDAQ:HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, including multiple oncology product candidates and a novel COVID-19 vaccine, today announced the appointment of Anthony Manning, Ph.D. as Chief Scientific Advisor. Dr. Manning will be responsible for strategic initiatives to accelerate the development of Heat Biologics' product portfolio. Dr. Manning brings over three decades of experience in immunology and autoimmune disease research and development. Most recently, Dr. Manning served as Chief Scientific Officer and Head of Research at M
5/10/21 7:30:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care

$HTBX
Press Releases

Fastest customizable press release news feed in the world

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35
DURHAM, N.C., May 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE:NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that Matthew Seavey, Ph.D., MBA, NightHawk's Vice President of Research will be presenting data on PTX-35, and serving on an expert panel discussing modes of Treg activation, at the 4th Annual Treg Directed Therapies Summit being held on May 17-19th in Boston. PTX-35 is a novel, potential first-in-class antibody immunomodulator of TNFRSF25 (death receptor 3), a receptor that is preferentially expressed by antigen-experienced T cells and can be utilized to expand regulator
5/10/22 8:00:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open Today
DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced that it has completed its name change from Heat Biologics, Inc. to NightHawk Biosciences, Inc. to better reflect the Company's evolution, including expansion of the therapeutic pipeline, vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effective today, May
5/3/22 7:00:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government
DURHAM, N.C., April 27, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian
4/27/22 8:00:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care

Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics
Elusys becomes wholly-owned biodefense subsidiary of NightHawk Plans to expand ANTHIM® distribution abroad DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced it has completed the acquisition of Elusys Therapeutics, Inc. a commercial-stage biodefense company and developer of ANTHIM® (obiltoxaximab), a treatment for inhalation anthrax. ANTHIM® is approved for use in the U.S. and Canada, and under the brand name Obiltoxaximab SFL in Europe and the United Kingdom. Nighthawk
4/20/22 8:00:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities
DURHAM, N.C., April 19, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company's evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effec
4/19/22 11:00:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics to Provide Corporate Update
DURHAM, N.C., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced CEO Jeff Wolf will host a conference call on Thursday, September 2nd at 11:00 A.M. Eastern Time to provide an update on the Company's activities. The conference call may be accessed by dialing 844-602-0380 for U.S. callers or +1 862-298-0970 for international callers. A webcast of the call may be accessed at https://www.webcaster4.com/Webcast/Page/2768/42602 or on the Company's website at https://ir.heatbio.com/. An audio replay of the call will be available th
8/30/21 7:30:00 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care

Heat Biologics (nighthawk Biosciences) Announces That Its Elusys Therapeutics Subsidiary Has Executed A Contract To Deliver ANTHIM To The Canadian Government For C$7.9M
Heat Biologics, Inc. (NYSE American: HTBX) (to be renamed "NightHawk Biosciences"), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system, today announced to shareholders that its Elusys Therapeutics subsidiary has finalized a contract with the Canadian government to deliver ANTHIM® (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack. ANTHIM® will be delivered to Canada's National Emergency Strategic Stockpile under a procurement contract totaling CAD $7.9 millioni. The goal of this program is to establish a Canadian supply of Anthim for use as a medical countermea
4/27/22 8:09:03 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics Announces Planned Name Change To NightHawk Biosciences; Will Trade Under Ticker 'NHWK' Effective May 3, 2022
Heat Biologics, Inc. ("Heat") (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing novel biodefense assets and first-in-class therapies to modulate the immune system, today announced that it is changing the name of the Company to NightHawk Biosciences, Inc., effective May 3, 2022, to better reflect the Company's evolution, including expansion of its therapeutic pipeline, the vertical integration of capabilities from drug discovery to manufacturing and commercialization, as well as the Company's new biodefense capabilities. In connection with the name change, the Company's ticker will change to "NHWK," effective May 3, 2022. The livestream event, held at the
4/19/22 11:01:08 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care
Heat Biologics' Subsidiary Outlines Development of New Commercial/Biodefense Biomanufacturing Facility
Heat Biologics Inc (NYSE:HTBX) announced a planned development partnership of its Scorpion Biological Services subsidiary with a private developer, the State of Kansas, and local and university affiliates. The Company intends to utilize the new 500,000+ square foot facility for large molecule and biologics manufacturing, focusing on biodefense. In addition to servicing the Company's product pipeline, it plans to operate as a full-service Contract Development and Manufacturing Organization (CDMO) to provide third-party manufacturing services on a fee-for-service basis. Also Read: Heat Biologics Issues New PTX-35 Preclinical Data In Organ Transplantation, Update On HS-110. Once fully o
4/18/22 10:29:28 AM ET
$HTBX
Biotechnology: Pharmaceutical Preparations
Health Care

Heat Biologics' Announces Planned Investor And Media Livestream Event To Discuss Latest Developments For April 19

Chat with this insight

Recent Analyst Ratings for $HTBX

$HTBX Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13D/A filed by Heat Biologics Inc. (Amendment)

SEC Form SC 13D/A filed by Heat Biologics, Inc. (Amendment)

$HTBX Leadership Updates

Live Leadership Updates

Heat Biologics Announces Appointment of Greg Burel, Former Director of the Strategic National Stockpile, to its Biothreat Advisory Board and as Senior Advisor to the Company

Heat Biologics Appoints Paul Tebbey as Senior Vice President of Product Development and Portfolio Strategy

Heat Biologics Appoints Anthony Manning, Ph.D. as Chief Scientific Advisor

$HTBX Press Releases

Fastest customizable press release news feed in the world

NightHawk Biosciences to Present at the 4th Annual Treg Directed Therapies Summit on PTX-35

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under "NHWK" Effective at the Market Open Today

Heat Biologics (NightHawk Biosciences) Announces that its Elusys Therapeutics Subsidiary has Executed a Contract to Deliver ANTHIM® to the Canadian Government

$HTBX Financials

Live finance-specific insights

$HTBX Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

$HTBX Market Insights

Live Market Insights

$HTBX Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$HTBX SEC Filings

Heat Biologics ("NightHawk Biosciences") Completes Acquisition of Elusys Therapeutics

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pipeline Expansion, Vertical Integration and New Biodefense Capabilities

Heat Biologics to Provide Corporate Update

Cantor Fitzgerald initiated coverage on Heat Biologics with a new price target

Cantor Fitzgerald initiated coverage on Heat Biologics

Alliance Global Partners reiterated coverage on Heat Biologics with a new price target

Heat Biologics (nighthawk Biosciences) Announces That Its Elusys Therapeutics Subsidiary Has Executed A Contract To Deliver ANTHIM To The Canadian Government For C$7.9M

Heat Biologics Announces Planned Name Change To NightHawk Biosciences; Will Trade Under Ticker 'NHWK' Effective May 3, 2022

Heat Biologics' Subsidiary Outlines Development of New Commercial/Biodefense Biomanufacturing Facility

SEC Form 4 filed by Wolf Jeffrey Alan

SEC Form 4 filed by Smith Edward B Iii

SEC Form 4 filed by Prendergast John K A

Heat Biologics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

Heat Biologics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

SEC Form 10-Q filed by Heat Biologics Inc.

Recent Analyst Ratings for
$HTBX

$HTBX
Large Ownership Changes

$HTBX
Leadership Updates

$HTBX
Press Releases

$HTBX
Financials

$HTBX
Analyst Ratings

$HTBX
Market Insights

$HTBX
Insider Trading

$HTBX
SEC Filings